Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Jazz Pharmaceuticals announces UK manufacturing investment
Due to open in 2024, the facility is designed to support the company’s two cannabis-based medicines and support future capacity for medicines under development
Regulatory
Hikma enters settlement agreement with Jazz for sodium oxybate
Jazz will grant Hikma and West-Ward the right to sell an authorised generic of Xyrem in the US
Design & Build
Jazz Pharmaceuticals among ISPE FOYA winners
Ardmac supplied and installed the cleanroom in the biopharmaceutical company's winning facility in Ireland
Finance
Jazz Pharmaceuticals buys Alize Pharma II for €18m
Alize Pharma II is developing treatments for acute lymphoblastic leukaemia
Pharmaceutical
Jazz Pharmaceuticals names Russell Cox as Chief Operating Officer
Cox was formerly EVP and Chief Commercial Officer at the biopharmaceuticals company
Manufacturing
Jazz Pharmaceuticals to build new manufacturing and development facility in Ireland
It is expected to open in 2016 and create up to 50 new jobs when fully operational
Ingredients
Jazz Pharmaceuticals moves to buy EUSA Pharma
Terms include $650 million in cash plus a potential $50 m milestone payment
Subscribe now